Effect of lack of interleukin-4, interleukin-12, interleukin-18, or the interferon-γ receptor on virus replication, cytokine response, and lung pathology during respiratory syncytial virus infection in mice

被引:39
作者
Boelen, A
Kwakkel, J
Barends, M
de Rond, L
Dormans, J
Kimman, T
机构
[1] Natl Inst Publ Hlth & Environm, Res Lab Infect Dis, NL-3720 BA Bilthoven, Netherlands
[2] Natl Inst Publ Hlth & Environm, Lab Pathol & Immunobiol, NL-3720 BA Bilthoven, Netherlands
关键词
RSV; mouse; IFN gamma; Th2; response; lung pathology;
D O I
10.1002/jmv.2180
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
RSV is an important cause of bronchiolitis in infants. Immunopathology may play a role in RSV-induced bronchiolitis and severe RSV-induced disease has been associated with a Th2 type immune response. The aim of the study was to identify cytokine pathways that are crucial in influencing RSV-induced disease. For that purpose we inoculated IFNgammaR(-/-), IL-12(-/-), IL-18(-/-), or IL-4(-/-) mice with RSV. We observed that an RSV infection resulted in a predominant Th1 cytokine response associated with slight bronchiolitis and alveolitis. Pulmonary histopathology was only aggravated in IFN R-/- mice, characterised by eosinophilic influx around the bronchioles. Despite subtle changes in cytokine expression, no differences in histopathology were observed in IL-12(-/-) and IL-18(-/-) mice. Deficiency of IL-4 has no effect on RSV-induced Th1 cytokines and pulmonary histopathology. IFNgamma-receptor deficiency during primary RSV infection resulted in a disturbed Th1 response based on increased IL-4, IL-5, and IL-13 expression and the presence of eosinophils in the lungs. It is concluded that IFNgamma signalling is required for a pronounced Th1 response to RSV while IL-12(-/-) and IL-18 are not. A shift in the balance between Th1 and Th2 towards a TH2 response induced by missing IFNgamma signalling leads to aggravated pulmonary pathology. This is not caused by enhanced viral load. (C) 2002 Wiley-Liss, Inc.
引用
收藏
页码:552 / 560
页数:9
相关论文
共 26 条
[1]   CYTO-TOXIC T-CELL RESPONSE TO RESPIRATORY SYNCYTIAL VIRUS IN MICE [J].
BANGHAM, CRM ;
CANNON, MJ ;
KARZON, DT ;
ASKONAS, BA .
JOURNAL OF VIROLOGY, 1985, 56 (01) :55-59
[2]   Both immunisation with a formalin-inactivated respiratory syncytial virus (RSV) vaccine and a mock antigen vaccine induce severe lung pathology and a Th2 cytokine profile in RSV-challenged mice [J].
Boelen, A ;
Andeweg, A ;
Kwakkel, J ;
Lokhorst, W ;
Bestebroer, T ;
Dormans, J ;
Kimman, T .
VACCINE, 2000, 19 (7-8) :982-991
[3]  
Collins P.L., 1996, FIELDS VIROLOGY, V3, P1313
[4]   Overexpression of interleukin-4 delays virus clearance in mice infected with respiratory syncytial virus [J].
Fischer, JE ;
Johnson, JE ;
KuliZade, RK ;
Johnson, TR ;
Aung, S ;
Parker, RA ;
Graham, BS .
JOURNAL OF VIROLOGY, 1997, 71 (11) :8672-8677
[5]   IMMUNE-RESPONSE IN MICE THAT LACK THE INTERFERON-GAMMA RECEPTOR [J].
HUANG, S ;
HENDRIKS, W ;
ALTHAGE, A ;
HEMMI, S ;
BLUETHMANN, H ;
KAMIJO, R ;
VILCEK, J ;
ZINKERNAGEL, RM ;
AGUET, M .
SCIENCE, 1993, 259 (5102) :1742-1745
[6]   Cytokines and T cells in host defense [J].
Hunter, CA ;
Reiner, SL .
CURRENT OPINION IN IMMUNOLOGY, 2000, 12 (04) :413-418
[7]   Th1 and Th2 cytokine induction in pulmonary T cells during infection with respiratory syncytial virus [J].
Hussell, T ;
Spender, LC ;
Georgiou, A ;
OGarra, A ;
Openshaw, PJM .
JOURNAL OF GENERAL VIROLOGY, 1996, 77 :2447-2455
[8]   Eosinophilic lung inflammation in particulate-induced lung injury: Technical consideration in isolating RNA for gene expression studies [J].
Kodavanti, UP ;
Jaskot, RH ;
Bonner, J ;
Badgett, A ;
Dreher, KL .
EXPERIMENTAL LUNG RESEARCH, 1996, 22 (05) :541-554
[9]   Molecular mechanisms and Th1/Th2 pathways in corticosteroid regulation of cytokine production [J].
Kovalovsky, D ;
Refojo, D ;
Holsboer, F ;
Arzt, E .
JOURNAL OF NEUROIMMUNOLOGY, 2000, 109 (01) :23-29
[10]   Intranasal IFN-γ gene transfer protects BALB/c mice against respiratory syncytial virus infection [J].
Kumar, M ;
Behera, AK ;
Matsuse, H ;
Lockey, RF ;
Mohapatra, SS .
VACCINE, 1999, 18 (5-6) :558-567